EGFR and glioblastoma: 56 of 100 IDH-wildtype diffuse gliomas without MVP or necrosis were defined as diffuse astrocytic glioma, IDH-wildtype, and further screened for EGFR amplification (Amp), +7/−10 and TERT promotor mutation, with 32 of them defined as molecular GBM.